請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41481完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李銘仁 | |
| dc.contributor.author | Yen-Hsin Chen | en |
| dc.contributor.author | 陳彥心 | zh_TW |
| dc.date.accessioned | 2021-06-15T00:20:24Z | - |
| dc.date.available | 2009-02-17 | |
| dc.date.copyright | 2009-02-17 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-02-10 | |
| dc.identifier.citation | 1. Fodor G., Kotrec M., et al. (2004). Hypertriglyceridemia. The Canadian Journal of Diagnosis, 84-93.
2. Lai C.Q., Tai E.S., and C.E. Tan et al. (2003). The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore, J Lipid Res 44, 2365–2373. 3. Aouizerat B.E., Kulkarni M., and Heilbron D. et al. (2003). Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids, J Lipid Res 44, 1167–1173. 4. Li G.P., Wang J.Y., and Yan S.K. et al. (2004). Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population. Clin Genet 65, 470–476. 5. Talmud P.J., Hawe E., and Martin S. et al. (2002). Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides, Hum Mol Genet 11, 3039–3046 6. Shachter Neil. S. (2001). Apolipoproteins C-I and C-III as important modulaors of lipoprotein metabolism. Current Opinion in Lipidology 12(3):297-304. 7. Tang Y., Sun P., and Guo D. et al. (2006). A genetic variant c.553G >T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride concentrations in a Chinese population. Atherosclerosis 185, 433–437 8. Alborn W.E., Prince M.J., and Konrad R.J. et al. (2007). Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes. Clin Chim Acta 378, 154-8. 9. McConathy W.J., Gesquiere J.C., and Bass H. et al. (1992). Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 33:995–1003. 10. Shoulders C.C., Harry P.J., and Lagrost L. et al. (1991). Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma concentrations of apo CIII. Atherosclerosis 87:239–47. 11. Waterworth D.M., Talmud P.J., and Bujac S.R. et al. (2000). Contribution of apolipoprotein C-III gene variants to determination of triglyceride concentrations and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol 20:2663–9. 12. Pennacchio L.A., Olivier M., and Hubacek J.A. et al. (2002). Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride concentrations. Hum Mol Genet 11:3031–8. 13. Nabika T., Nasreen S., and Kobayashi S. et al. (2002). The genetic effect of the apolipoprotein AV gene on the serum triglyceride concentration in Japanese. Atherosclerosis 165:201–4. 14. Ribalta J., Figuera L., and Fernandez-Ballart J. et al. (2002). Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem 48:1597–600. 15. Qi L, Liu S, and Hunter D. et al. (2007). Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol concentrations in women with type 2 diabetes. Atherosclerosis 192:204–10. 16. Kao J.T., Wen H.C., and Chien K.L. et al. (2003). A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 12:2533–9. 17. Tybjaerg-Hansen A., Nordestgaard B.G., and Gerdes L.U. et al. (1993) Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 100:157–69. 18. Hayden M.R., Kirk H., and Clark C. et al. (1987). DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet 40:421–30. 19. Wojciechowski A.P., Farrall M., and Cullen P. et al. (1991). Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23–q24. Nature 349:161–4. 20. Wijsman E.M., Brunzell J.D., and Jarvik G.P. et al. (1998). Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler Thromb Vasc Biol 18:215–26. 21. Eichenbaum-Voline S., Olivier M., and Jones E.L. et al. (2004). Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 24:167–74. 22. Hallman D.M., Srinivasan S.R., and Chen W. et al. (2006). Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study. Metabolism 55(12):1574-81. 23. Schaap F.G., Nierman M.C., and Berbée J.F. et al. (2006). Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res 47(10):2333-9 24. Onat A., Hergenc G., and Sansoy V. et al. (2003). Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 168:81-89. 25. Chien K.L., Fang W.H., and Wen H.C. et al. (2008). APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese. Clin Chim Acta 390(1-2):56-62. 26. Matsunaga A., Arishima H., and Niimura H. et al. (2007). Strong linkage disequilibrium and association of -1131T>C and c.553G>T polymorphisms of the apolipoprotein A5 gene with hypertriglyceridemia in a Japanese population. Circ J. 71(5):746-52. 27. Liu H.K., Li X.F., and Zhang S.Z et al. (2005). Association of Sst I polymorphism in apolipoprotein C3 gene with hypertriglyceridaemia in coronary atherosclerotic heart disease and type II diabetes mellitus in Chinese population. Yi Chuan Xue Bao 32(1):11-8. 28. Pieur X., Coste H., and Rodriguez J.C. et al. (2003) The human apolipoprotein AV gene is regulated by peroxisome proliferators-activated receptor-α and contains a novel farnesoid X-activated response element. J Biol Chem 278: 25468-25480 29. Alborn W.E., Sloan J.H., and Konrad R.J. et al. (2005) The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated with VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared with Other Apolipoproteins. Clin Chem 51: 351-359. 30. Garber A.M. (1994). Triglyceride concentration and coronary heart Disease. BMJ 309:2-3. 31. Haymore Bert R., jonathan R., and Thomas G. et al. (2005). Clinical review article:Hypertriglyceridemia. Hospital Physicians 17-24. 32. Miller M. (1998). Is hypertriglyceridemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 19:H18-22. 33. Assmann G., Schulte H., and Funke H. et al. (1998). The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19:M8-M14. 34. Schulte H., Cullen P., and Assmann G. et al. (1999). Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM). Atherosclerosis 144:199-209. 35. 唐正乾。郭傑。陳滄山。許世元。(2007)。過氧小體增殖活化受體、代謝症候群與癌症。 內科學誌。第十八卷：五期。第244-255頁。 36. S Chhabra, R Narang, LR Krishnan, S Vasisht, DP Agarwal,LM Srivastava, SC Manchanda and N Das. (2002). Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC GENETICS 3:1-6. 37. Breslow J.L., Zannis V.I., and SanGiacomo T.R. et al. (1982). Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J. Lipid Res 23: 1224 - 1235. 38. Davignon J., Gregg R.E., and Sing C.F. et al. (1988). Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1-21. 39. Yamauchi K., Tozuka M., and Nakabayashi T. et al. (1999). Apolipoprotein E in Cerebrospinal Fluid: Relation to Phenotype and Plasma Apolipoprotein E Concentrations. Clin Chem 45: 497-504. 40. Corder E.H. et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-3. 41. Saunders, A. M., Strittmmatter W.J., and Schmechel D. et al. (1993). Apolioprotein E allele e4 with lateonset familial and sporadic Alzheimer's disease. Neurology 43:1467-72 42. Cruts M., Van Broeckhoven C. (1998). Molecular genetics of Alzheimer's disease. Ann Med 30(6):560-5. 43. St George-Hyslop P.H. (2000). Molecular genetics of Alzheimer's disease. Biological psychiatry 47(3):183-99. 44. Luksiene D.I., Cerniauskiene L.R., and Margeviciene L. et al. (2008). Changes in the prevalence of metabolic syndrome and smoking habits during a 10-year period and relation between these risk factors and ischemic heart disease among men aged 45-64 years. Medicina (Kaunas), 44(5):400-6. 45. Moro E., Gallina P., and Pais M. et al. (2003). Hypertriglyceridemia is associated with increased insulin resistance in subjects with normal glucose tolerance: evaluation in a large cohort of subjects assessed with the 1999 World Health Organization criteria for the classification of diabetes. Metabolism. 52(5):616-9. 46. Matsuhisa M., Yamasaki Y., and Emoto M. et al. (2007). A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract. 77(1):151-4. 47. Akira Matsunagac. (2007). Strong linkage Disequilibrium and Associated of -1131T>C and c.553G>T Polymorphism of the Apolipoprotein A5 Gene With Hypertriglyceridemia in a Japanese Population. Circ J 71:746-752. 48. Marinez Oliveira. (2008). Interaction between APOA5 -1131T>C and APOE polymorphism and their association with severe hypertriglyceridemia. Clinica Chemica Acta 395:68-71 49. Huang Meng-Chuan, Wang Tsu-Nai, and Wang Huan-Sen et al. (2008). The -1131T>C Polymorphism In The Apolipoprotein A5 Gene Is Related To Hypertriglyceridemia In Taiwanese Aborigines. Kaohsiung J Med Sci 24:171-178. 50. Clive R. Pillinger, et al. (2008). An apolipoprotein in A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res 49:1846-1854. 51. Chien Kuo-Liong, Fang Woei-Horng, and Wen Hui-Chin et al. (2008). APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese. Clinica Chemica Acta 390:5-62. 52. Miek C. Jong, Marten H. Hofker and Louis M. Havekes. (1999). Role of ApoCs in Lipoprotein Metabolism : Functional Differences Between ApoC1, APOC2, and APOC3. Journal of the American Heart Association 19:472-484. 53. Richard B. Weinberg, Victoria R. Cook, Jennifer A, Beckstead, Dale D. O. Martin, James W. Gallagher, Gregory S. Shelness, and Robert O. Ryan. (2003). Structure and Interfacial Properties of Human Apolipoprotein A-V. The Journal of Biological Chemistry 278(36):34438-34444. 54. Kao Jau-Tsuen, Wen Hui-Chin, and Chien Kuo-Liong et al. (2003). A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Human Molecular Genetics 12(19):2533-2539. 55. Merkel M., Loeffler B, and Kluger M. et al. (2005). Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceride-rich Lipoprotein by Interaction with Proteoglycan-bound Lipoprotein Lipase. The Journal of Biological Chemistry 280(22):21553-21560. 56. Lins L., Flore C., and Chpelle L. et al. (2002). Lipid-interacting properties of N-terminal domain of human apolipoprotein C-III. Protein Eng 15:513-520. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41481 | - |
| dc.description.abstract | 由於現代人的飲食習慣與以往大為不同，加上忙碌的生活導致缺乏運動，以及一些抽菸、喝酒等生活習慣，使得代謝症候群的病人越來越多。其中常見的高血脂症(Hypertriglyceridemia，HTG)的發生不單單只受到後天環境因素的影響，先天遺傳基因也會造成三酸甘油脂(Triglycerides，TGs)升高；而TGs升高與心血管疾病(Coronary Artery Disease，CAD)及腦血管疾病(Cerebrovascular Disease)的相關性相當顯著(4,7,10,,17,24,31,55)。因此探究高血脂症的發生原因和先天性基因型的相互作用為我們重要之課題。
首先，我們在代謝門診經專科醫師之診斷與協助，收集Controls (TGs<2.26mmol/L, n=285)，Moderate HTG (2.26≦TGs<5.65 mmol/L, n=216)，以及Severe HTG (TGs≧5.65mmol/L, n=169)三組之病患及對照組的檢體，並加以瞭解其基本資料和生活模式後，發現在年齡、BMI、腰圍、抽菸習慣和有無高血壓病史和HTG具有統計學的顯著相關(p-value<0.0001)，推論這些因素都可能會造成TGs升高，而引發高血脂症。接著，從臨床生化的檢驗數值發現，Severe HTG的病人在膽固醇(CHO)、TGs、飯前血糖(Glucose AC)和飯前胰島素(Insulin AC)上的表現比Moderate HTG和Control的病人較高(p-value<0.0001)，由此可見，血脂越高的病人在這些生化數值上的表現也都相對提高。 探討後天環境的影響和臨床表徵之後，我們根據文獻選取與高血脂症發生有關的APOA5、APOE、APOC3三個候選基因(Candidate Gene)進行分析。若在APOA5基因上出現553G>T的polmorphism(APOA5:T(+))時，脂蛋白A5 (Apoliprotein A5)無法調節TGs的運輸，導致TGs升高；在APOC3基因的三端未轉錄區若有3238C>G的置換(S2基因型)時，脂蛋白C3 (Apolipoprotein C3)失去調控TGs代謝的功能，造成TGs升高；而在APOE基因上，倘若為APOE4的基因型態，在運送和代謝TGs、CHO的能力會變差，而使得血液中TGs的濃度升高。我們發現血脂表現越高，有APOA5之”T” allele及APOE4 allele的比例，在統計上明顯地增高(p-value<0.0001)。 因為APOA5、APOE4和APOC3皆可能與高血脂症之發生有相關，所以利用Univariate and Multivariate Logistic Regression Aalysis去分析三個基因之間是否有交互作用，結果發現為APOA5:T(+)、APOC3:S2和APOE4基因型態時，最有機會造成高血脂症之發生，推論APOA5蛋白和APOE4同時存在，會造成TGs的調控不好，導致TGs升高。 在脂蛋白元E4、C3和A5的表現上，發現脂蛋白C3的濃度與Lipid Profile(CHO、TGs、NHDL)的表現，具有統計意義(p-value<0.0001)，且脂蛋白元C3在TGs大於500 mg/dl的HTG表現會比血脂小於500 mg/dl的群體來的高。所以脂蛋白元C3的濃度與高血脂症有相關。 在發現APOA5、APOC3和APOE4與高血脂症之關係後，我們可以建議高血脂症的病人進行基因型態之分析，幫助高血脂症病人之家屬改變飲食習慣和生活作息，以降低體內的血脂濃度，避免高血脂症之發生。對於病人，可以找到其高血脂症發生的原因，在併發症和情形尚未惡化之前，就接受治療，控制血脂，改善生活品質，並預防心血管疾病之發生。 | zh_TW |
| dc.description.abstract | The differences in eating habits and less exercise influence people’s health condition. The increasing people suffered from metabolic syndrome including Hypertriglyceridemia (HTG) which results from genetic and environmental factors. Some researches say that the elevated triglycerides (TGs) are related to coronary artery disease (CAD) and cerebrovascular disease. We supposed to do is consider what caused HTG and clarify the interaction of genotypes.
We collect three groups of Controls (TGs<2.26mmol/L, n=285), Moderate HTG (2.26≦TGs<5.65 mmol/L, n=216), and Severe HTG (TGs≧5.65mmol/L, n=169) from Dr. Su’s metabolic clinic in National Taiwan University Hospital. Get information of their age, BMI, waist, smoking habit and the history of hypertension associated with HTG patients, and identify their significance in statistics (p-value<0.0001). And then consider the biochemical analysis, we find the expressions of cholesterol (CHO), TGs, Glucose AC, Insulin AC in severe HTG are higher than moderate HTG and Controls (p-valus<0.0001). According to previous papers, we pick up three candidate gene (APOA5, APOE and APOC3) to do genetic analysis. If we find the 553G>T polymorphism in APOA5 gene, apolipoprotin A5 cannot modulate the transport of TGs and cause TGs increase. The replacement of C to G occurred in 3’ untranslated region at 3238 site of APOC3 gene, which make apolipoprotein C3 fail to regulate TGs metabolism. The consequence is TGs elevated. And if the genotype is APOE4, the function of TGs transport and metabolism will not work well and the concentration of TGs will be high. There are statistic significances (p-value<0.0001) in high ratio of T allele in APOA5 and APOE4 allele. Consequently, APOA5, APOE4 and APOC3 may be related to HTG. Therefore we use univariate and multivariate logistic regression analysis to analyze the interaction between these three genes. We postulate the co-existence of apoliprotein A5 and apolipoprotein E4 influence the function of TGs regulation and then TGs increase. Otherwise, we also observe the protein level of apolipoprotein E4, C3 and A5. Then, we find that the concentration of apolipoprotein C3 is associated with lipid profile (p-value<0.0001). As a result, we assume that the level of apolipoprotein C3 is associated with TGs level in HTG patients. Clarify APOA5, APOE4, and APOC3 are associated with HTG. What we should do is suggest the patients with HTG do genetic analysis to confirm genotype, and then help them change their life style to control TGs level and avoid coronary artery disease. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T00:20:24Z (GMT). No. of bitstreams: 1 ntu-98-P95448013-1.pdf: 446364 bytes, checksum: 5fcd21d750f61d38580b574a91c33128 (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 口試委員會審定書………………………………………………… i
誌謝………………………………………………………………… ii 中文摘要…………………………………………………………… iii 英文摘要…………………………………………………………… v 第一章、緒論……………………………………………………… 1 ㄧ、高血脂症簡介…………………………………………… 1 二、三酸甘油脂介紹………………………………………… 5 三、高血脂症治療方式……………………………………… 5 四、高血脂症發生率………………………………………… 6 五、高血脂症之分子遺傳…………………………………… 7 第二章、 材料與方法……………………………………………… 9 ㄧ、儀器……………………………………………………… 9 二、試劑……………………………………………………… 9 三、檢體來源………………………………………………… 9 四、高血脂症病人臨床表徵之收集………………………… 10 五、DNA萃取與限制酶切割………………………………… 10 六、ELISA方法……………………………………………… 13 七、統計學方法……………………………………………… 23 第三章、 結果…………………………………………………… 25 第四章、 討論…………………………………………………… 31 附表………………………………………………………………… 34 參考文獻…………………………………………………………… 44 | |
| dc.language.iso | zh-TW | |
| dc.subject | 三酸甘油脂 | zh_TW |
| dc.subject | 心血管疾病 | zh_TW |
| dc.subject | 候選基因 | zh_TW |
| dc.subject | 多型態 | zh_TW |
| dc.subject | 脂蛋白元A5 | zh_TW |
| dc.subject | 脂蛋白元C3 | zh_TW |
| dc.subject | 高血脂症 | zh_TW |
| dc.subject | 脂蛋白元E4 | zh_TW |
| dc.subject | hypertriglyceridemia (HTG) | en |
| dc.subject | APOC3 | en |
| dc.subject | APOA5 | en |
| dc.subject | candidate gene | en |
| dc.subject | polymorphism | en |
| dc.subject | cerebrovascular disease | en |
| dc.subject | coronary artery disease (CAD) | en |
| dc.subject | triglycerides (TGs) | en |
| dc.subject | APOE4 | en |
| dc.title | 高血脂症病人的分子基因學研究及相關脂蛋白之表現 | zh_TW |
| dc.title | Molecular Analysis of the Taiwanese Patients with Hypertriglyceridemia and Expression of the Associated Apolipoprotein | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 余家利,蘇大成 | |
| dc.subject.keyword | 高血脂症,三酸甘油脂,心血管疾病,候選基因,多型態,脂蛋白元A5,脂蛋白元C3,脂蛋白元E4, | zh_TW |
| dc.subject.keyword | hypertriglyceridemia (HTG),triglycerides (TGs),coronary artery disease (CAD),cerebrovascular disease,candidate gene,APOA5,APOC3,APOE4,polymorphism, | en |
| dc.relation.page | 49 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-02-10 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 435.9 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。